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RNAi Transfection Results in Lipidome Changes
Cagakan O¨zbalci, Elisabeth M. Storck, and Ulrike S. Eggert*
RNAi experiments are ubiquitously used in cell biology and are achieved by
transfection of small interfering RNAs (siRNAs) into cells using a transfection
reagent. These results in knock-down of proteins of interest, and the
phenotypic consequences are then analyzed. It is reported here that two
common RNA interference (RNAi) transfection reagents, DharmaFECT 1 and
INTERFERin, in mock transfections using non-targeting siRNAs, cause
alterations in the lipidome of HeLa cells. Some lipids change in response to
both, presumably chemically different, transfection reagents, while other lipid
species change only in response to one of the reagents. While the functional
implications of these lipidomic alterations remain to be investigated, the
authors’ experiments suggest that it is important to use appropriate mock
transfection controls during RNAi experiments, ideally complemented by an
orthogonal perturbation, especially when investigating membrane-associated
phenomena.
RNA interference (RNAi) is very commonly used in cell biology
to deplete cellular proteins by destroying mRNA encoding a
protein of interest. Tens of thousands of articles have been
published using RNAi, which complements other methods to
perturb protein function such as small molecule treatments
and genetic manipulations like CRISPR/Cas9 knockouts.[1] In
an RNAi experiment, small interfering RNAs (siRNAs) are
introduced into cells using commercially available transfection
reagents (TRs). The composition of these TRs is proprietary; they
often include cationic lipids or polymers to facilitate transfer
of negatively charged siRNAs across the plasma membrane.
Researchers typically empirically determine the best transfection
conditions for their cell type and target protein by varying the
TR, concentration, and treatment time.
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Membrane-associated proteins play
many important roles in cells, and it
is becoming increasingly clear that the
lipid components of membranes are
also important.[2] Changes in membrane
proteins or lipids can have substantial
effects on cellular physiology. While
lipid biosynthesis is complex and poorly
understood, it is clear that cells can re-
spond to and adapt their lipidomes when
exposed to different stimuli and many
studies have explored lipidome changes
in response to protein perturbation by
RNAi (e.g., ref. [3]). With so much new
cell biology being discovered through
RNAi experiments, we wondered if
the process of siRNA transfection, in
the absence of any protein depletion,
affected the lipid composition of cells.
This would have profound implications
on the experimental design of studies involving membrane pro-
teins and lipids.
We test here the hypothesis that TRs used in siRNA knock
down experiments may affect the cellular lipidome. We per-
formed mock siRNA transfections and then analyzed lipidome
changes. We chose a very commonly used cultured cell line,
HeLa, and two different commonly used TRs (DharmaFECT
1 and INTERFERin) for our analysis. Usually the TR is com-
plexed with siRNA before addition to cells and this complex
may have different properties, such as the ability to enter cells,
than the TR alone. Therefore, HeLa cells were treated with the
TRs alone or complexed with non-targeting (NT) siRNA for 72 h
(Figure 1a,b). To confirm that the experimental conditions re-
sult in successful RNAi, we optimized our transfection proto-
cols using target-specific siRNAs for three cell division-associated
proteins we routinely study in our lab (RACGAP1, Anillin,
and CAPZB, Figure S1, Supporting Information).[4] Immunoblot
analyses of total cell lysates illustrate that our protocol achieves
penetrant protein knock down and that the knock down efficiency
is comparable for both TRs (Figure S1, Supporting Information).
Importantly, no cell toxicity was evident at the concentrations of
TR used.
With our optimized transfection protocol in hand, we per-
formed siRNA transfections and subsequently extracted lipids
for lipidomic analysis. Samples were prepared in two indepen-
dent experiments with three replicates of each condition. First,
cells grown in 6-well dishes were washed with cold PBS, scraped,
and transferred to a microfuge tube. An aliquot was taken for
protein concentration determination. Because it is difficult to
accurately determine overall lipid concentrations, samples for
lipidomic analysis were normalized based on protein concentra-
tion. The cell samples were pelleted, re-suspended in PBS, and
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Figure 1. Experimental workflow and conditions used in this study and initial data analysis. A) Cartoon of the workflow used in this study. Cultured HeLa
cells were subjected to RNAi for 72 h. Cells were scraped into a micro-centrifuge tube and subjected to a two-step chloroform/methanol lipid extraction
protocol. Extracts were analyzed by reversed phase liquid chromatography-mass spectrometry (LC-MS). MS/MS confirmation or relative quantification
was performed to identify lipid species altered in experimental conditions versus untreated control cells. B) The transfection conditions tested in this
study. Two different transfection reagents (INTERFERin and DharmaFECT 1) were tested on their own or in combination with non-targeting siRNA (NT).
Untreated cells served as a control. C) Principal component analysis representing the separation of untreated HeLa cells from HeLa cells treated with
INTERFERin (top panels) or DharmaFECT 1 (bottom panels) and TRs plus NT siRNAs in positive (left panels) and negative (right panels) modes. PCA
plots were generated by nontargeted analysis with one-way ANOVA p (Corr) (cut-off = 0.05) test.
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Figure 2. Targeted lipid class analysis of untreated HeLa cells andHeLa cells treated with transfection reagents. Comparison of major lipid class raw total
intensities in A) untreated, INTERFERin and INTERFERin plus NT siRNA-treated HeLa and B) untreated DharmaFECT 1 and DharmaFECT 1 plus NT
siRNA-treated HeLa. Less abundant species are shown in right panels. Error bars indicate +/- SEM (n = 6). Significance analysis and multiple compar-
isons were performed by ANOVA and Dunnet tests with p-value style< 0.0021(**),< 0.0002(***). Cer, ceramide; DG, diacylglycerol; FA, fatty acid; GM3,
Ganglioside GM3; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS, phosphatidylserine;
SM, sphingomyelin; TG, triacylglycerol.
spiked with an internal lipid standard (d5-TG ISTD Mix I) for
quality control of the extraction process and as a reference for
lipidomics. To obtain both hydrophobic and amphiphilic lipids,
we used a 2-step extraction method.[5] In the first step, we added
chloroform:methanol (10:1, v/v) to the cell suspensions and
recovered the lower organic phase. The upper aqueous phase
was re-extracted with chloroform:methanol (2:1, v/v) (Figure 1A).
The lipid extracts were evaporated under a stream of nitrogen,
reconstituted in loading buffer (isopropanol:water:acetonitrile,
2:1:1) and analyzed by reversed phase liquid chromatography-
mass spectrometry (RP LC-MS).
We analyzed samples by RP LC-MS analysis using a 1290
Infinity UHPLC system coupled to a 6550 iFunnel quadrupole
time-of-flight mass spectrometer (LC QTOF MS) from Agilent
Technologies. Extracted lipids were separated on an Acquity
UPLC CSH C18 column (100 × 2.1 mm, 1.7 μm) (Waters)
and features were detected in negative and positive modes.
Analytical conditions and mass spectrometric parameters were
adapted from Cajka and Fiehn[6] with minor modifications (see
Experimental Methods in SI). We injected samples in random
order to avoid systematic contamination and included controls of
TR only. The features detected in these samples (due to TRs and
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Figure 3. Lipid species altered in TR-treated compared to untreated HeLa cells. A) Significantly altered lipid species in INTERFERin and INTERFERin plus
NT siRNA-treated HeLa cells. B) Significantly altered lipid species in DharmaFECT 1 and DharmaFECT 1 plus NT siRNA-treated cells. Six independent
samples from two separate experiments were run for each condition. Statistical analysis was performed in Mass Profiler Professional as detailed in the
Experimental Methods and ion counts of altered species were re-extracted in Profinder. Fold change was calculated by normalizing the mean ion count
of treated samples (n = 6) to the mean ion count of untreated samples (n = 6). Error bars represent SD. Lipid species indicated with red arrows are
increased in both INTERFERin and DharmaFECT 1 treated cells. Lipid species indicated by black asterisks (*) were predicted by METLIN metabolomics,
LipidBlast or LIPID MAPS databases using accurate mass and were not confirmed by MS/MS. 1) Two species of Cer d43:1 were detected but side-chain
composition could not be resolved by MS/MS. See Figures S4 (DharmaFECT 1) and S5 (INTERFERin), Supporting Information for graphs showing all
analyzed lipid species. Cer, ceramide; DG, diacylglycerol; FA, fatty acid; GM3, Ganglioside GM3; PC, phosphatidylcholine; PE, phosphatidylethanolamine;
PG, phosphatidylglycerol; TG, triacylglycerol.
MS solvents) (Figure S2 and Table S1, Supporting Information)
were removed from subsequent analyses.
We first performed a principal component analysis (PCA)
on our data sets to determine overall differences. Interestingly,
each set of conditions with both TRs (untreated HeLa, HeLa
treated with TR, and HeLa treated with TR complexed to NT
siRNA) clustered separately, both in positive and negativemodes,
supporting our hypothesis that TRs may impact cellular
lipidomes (Figure 1C). Unexpectedly, the presence of NT siR-
NAs also affected lipidomes, with clear separate clusters for these
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conditions. The only variable in these experiments was the pres-
ence or absence of NT siRNA. The function of a TR is to com-
plex siRNA and carries it across the plasma membrane, and this
is what it has been optimized for. Therefore, it is possible that
the cellular uptake of the complex is more efficient than that of
the TRs alone and they may access cellular membrane structures
differently. Our analysis cannot differentiate between these pos-
sibilities as it captures the total cellular lipidome and does not
resolve subcellular compartments. It is also possible that the NT
siRNAs target unknown miRNAs or have off-target effects even
though they have been designed to not target human mRNAs,
which could be addressed by analyzing NT siRNAs with differ-
ent sequences. More broadly, there remains much to be learned
about themolecular mechanisms of siRNA transfection and sub-
sequent dissociation of the siRNA from the TR, which may be
needed for the silencing reaction to occur. It has been challeng-
ing to address these questions in part due to the proprietary com-
position of the TRs and in part due to a lack of experimental tech-
niques that would allow a step by step analysis.
Having shown that both TR and TR plus NT siRNA resulted
in overall changes to the lipidome, we next determined if specific
lipid families or species were changed. We applied untargeted
analysis followed by a complementary targeted data analysis for
common lipid classes and species. We used an in-house database
that includes MS/MS data correlated with retention times to
identify lipid species (e.g., Figure S3, Supporting Information)
and analyzed the data as reported in the Experimental Methods
in the Supplementary Materials. Most lipid classes were broadly
unaffected. There were no significant changes to lipid families
after INTERFERin treatment, while TGs, DGs, and FAs changed
slightly but significantly after DharmaFECT 1 plus NT siRNA
treatment (Figure 2). This is consistent with a large body of liter-
ature based on the assumption that control siRNA transfections
do not generally grossly perturb cellular phenotypes.
Interestingly, we found numerous individual lipid species
changed in response to TR treatments (Figure 3; see Figures
S4 and S5, Supporting Information, for graphs showing fold
changes for all species analyzed in the targeted analysis and
Tables S2 and S3, Supporting Information, for details on the
changed species). As noted during PCA analysis TR plus NT
siRNA treatment differed from TR alone and the effects on spe-
cific species we observed were generally stronger in the TR plus
siRNA treatments (Figure 3). Remarkably, three lipid species
changed in response to treatment with both TRs (Figure 3 and
Table S1, Supporting Information): FA 24:5 and 2 PG species (out
of many PG species detected): PG 22:5 22:6 and PG 16:1 22:6.
Taken together, our data show that cells can adapt their
lipidomes in response to treatment with TRs. Several different
responses are possible and may occur in parallel. First, cells
could alter their lipid metabolism to adapt to changes in cellular
membrane properties, such as membrane fluidity or permeabil-
ity changes, caused by TRmolecules inserting into or interacting
with membrane components. It is possible that the three lipids
that change in all TR samples are a consequence of such an adap-
tation since these lipids change independently of the chemical
identity of the transfection reagent. Second, it is conceivable that
TR components could be metabolized and/or be incorporated
into lipid structures. It is difficult to evaluate this possibility with-
out knowing the proprietary composition of the TRs, but we did
not see any large peaks corresponding to unnatural lipids, sug-
gesting this effect is limited. Third, the overall health of the cell
may be affected after transfection and responses such as apopto-
sis could be triggered. Our cells looked healthy and grew well and
we saw no obvious signs of TR toxicity. However, we did observe
an increase in TGs andDGs after DharmaFECT 1 plus NT siRNA
treatment, a lipid change also observed during cell death.[7] It is
possible that subtle changes towards apoptotic initiation occurred
in this treatment.
The functional implications of the lipid changes we report here
require further examination, and theremay bemany cases where
there is no effect on the biology under investigation. However,
common sense would suggest that RNAi experiments are always
accompanied by controls where amock transfection is performed
in parallel, as is already being done bymany careful investigators.
In cases where a phenotypic consequence of lipid alterations is
suspected, we would suggest using multiple TRs and ideally con-
firming results by an orthogonal method such as shRNA (which
can be used to create stable cell lines) or CRISPR/Cas9.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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